国产亚洲综合一区二区在线观看_免费看成年AAA级毛片_艳妇臀荡h乳欲伦交换漫画_亚洲中国成人影院_午夜无码福利片国产播放_成人亚洲欧美日韩_狠狠躁天天躁无码中文幕_在线内射色网视频_免费的黄漫18禁动漫网站_无遮挡又黄又爽又刺激视频

<fieldset id="oq022"></fieldset><ul id="oq022"><sup id="oq022"></sup></ul>

<fieldset id="oq022"><menu id="oq022"></menu></fieldset>

<del id="oq022"><tfoot id="oq022"></tfoot></del>

For Patients, For the Unmet
We Innovate

For Patients, For the Unmet
We Innovate

For Patients, For the Unmet
We Innovate

01

03

時邁藥業(yè)

時邁藥業(yè)

時邁藥業(yè)

時邁藥業(yè)

時邁藥業(yè)

時邁藥業(yè)

時邁藥業(yè)

時邁藥業(yè)

時邁藥業(yè)

CentryMed
Featured Technologies

Explore More

時邁藥業(yè)

時邁藥業(yè)

時邁藥業(yè)

時邁藥業(yè)

時邁藥業(yè)

Targeted Activation

Our proprietary Pro-BiTE? platform activates
Tcells selectively within the tumor
microenvironment (TME),
Safer Treatment

significantly reducing systemic toxicity and
unlocking safer T-cell therapies for solid
tumors.

Core Technologies
And Pipelines

時邁藥業(yè)

Core Innovative Antibody Platform

Independently build four core platform technologies with global competitiveness

時邁藥業(yè)

Product Pipeline

Independently build four core platform technologies with global competitiveness

Latest News

Shimai Pharma Presents DNV3 (LAG-3 Antibody) Combination Therapy Results for Melanoma at ASCO 2025 Annual Meeting

Shimai Pharma Presents SMET12 (EGFR×CD3 Bispecific Antibody) Combination Therapy Results for Advanced NSCLC at ASCO 2025 Annual Meeting

CentryMed to Present Clinical Data on SMET12 and DNV3 at 2025 ASCO Annual Meeting

<cite id="seoqg"><abbr id="seoqg"></abbr></cite>

<ul id="seoqg"></ul>

<fieldset id="seoqg"><menu id="seoqg"></menu></fieldset>